521 related articles for article (PubMed ID: 16110326)
1. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.
Grode L; Seiler P; Baumann S; Hess J; Brinkmann V; Nasser Eddine A; Mann P; Goosmann C; Bandermann S; Smith D; Bancroft GJ; Reyrat JM; van Soolingen D; Raupach B; Kaufmann SH
J Clin Invest; 2005 Sep; 115(9):2472-9. PubMed ID: 16110326
[TBL] [Abstract][Full Text] [Related]
2. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.
Gengenbacher M; Vogelzang A; Schuerer S; Lazar D; Kaiser P; Kaufmann SH
mBio; 2014 Jun; 5(3):e01262-14. PubMed ID: 24895310
[TBL] [Abstract][Full Text] [Related]
3. The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice.
Rao M; Vogelzang A; Kaiser P; Schuerer S; Kaufmann SH; Gengenbacher M
PLoS One; 2013; 8(11):e78966. PubMed ID: 24236077
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes.
Hess J; Miko D; Catic A; Lehmensiek V; Russell DG; Kaufmann SH
Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5299-304. PubMed ID: 9560270
[TBL] [Abstract][Full Text] [Related]
5. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
Gengenbacher M; Nieuwenhuizen N; Vogelzang A; Liu H; Kaiser P; Schuerer S; Lazar D; Wagner I; Mollenkopf HJ; Kaufmann SH
mBio; 2016 May; 7(3):. PubMed ID: 27222470
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
Deng YH; He HY; Zhang BS
J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
[TBL] [Abstract][Full Text] [Related]
8. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
[TBL] [Abstract][Full Text] [Related]
9. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses.
Desel C; Dorhoi A; Bandermann S; Grode L; Eisele B; Kaufmann SH
J Infect Dis; 2011 Nov; 204(10):1573-84. PubMed ID: 21933877
[TBL] [Abstract][Full Text] [Related]
10. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
[TBL] [Abstract][Full Text] [Related]
11. Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis.
Gengenbacher M; Kaiser P; Schuerer S; Lazar D; Kaufmann SH
Microbes Infect; 2016 May; 18(5):364-8. PubMed ID: 26994939
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
Deng YH; He HY; Zhang FJ
Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
[TBL] [Abstract][Full Text] [Related]
13. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine's superior protection against tuberculosis.
Vogelzang A; Perdomo C; Zedler U; Kuhlmann S; Hurwitz R; Gengenbacher M; Kaufmann SH
J Infect Dis; 2014 Dec; 210(12):1928-37. PubMed ID: 24943726
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
[TBL] [Abstract][Full Text] [Related]
15. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
[TBL] [Abstract][Full Text] [Related]
16. The Recombinant BCG ΔureC::hly Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation.
Saiga H; Nieuwenhuizen N; Gengenbacher M; Koehler AB; Schuerer S; Moura-Alves P; Wagner I; Mollenkopf HJ; Dorhoi A; Kaufmann SH
J Infect Dis; 2015 Jun; 211(11):1831-41. PubMed ID: 25505299
[TBL] [Abstract][Full Text] [Related]
17. [Strategies for the development of new tuberculosis vaccines].
Fattorini L
Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
[TBL] [Abstract][Full Text] [Related]
18. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy.
Grode L; Kursar M; Fensterle J; Kaufmann SH; Hess J
J Immunol; 2002 Feb; 168(4):1869-76. PubMed ID: 11823521
[TBL] [Abstract][Full Text] [Related]
20. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
